作者
Sunil V. Rao,Bodo Kirsch,Deepak L. Bhatt,Andrzej Budaj,Rosa Coppolecchia,John W. Eikelboom,Stefan James,W. Schuyler Jones,Béla Merkely,Lars Keller,Renicus S. Hermanides,Gianluca Campo,José Luis Ferreiro,Tadao Shibasaki,Hardi Mundl,John H. Alexander,C Hengstenberg,Clemens Steinwender,Hannes Alber,Regina Steringer‐Mascherbauer,Andreas Schober,Johann Auer,Franz Xaver Roithinger,Dirk von Lewinski,Deddo Moertl,Kurt Huber,Patrick Coussement,E Hoffer,Christophe Beauloye,Luc Janssens,Pascal Vranckx,Herbert De Raedt,Thomas Vanassche,Matthias Vrolix,Richard Rokyta,Jiří Pařenica,Radek Pelouch,Zuzanna Motovska,David Alan,Jiří Kettner,Rostislav Polášek,Ondřej Čermák,Pavel Sedloň,Jiří Haniš,Martin Novák,Jan Bělohlávek,Thomas Horacek,Stefan Stadler,Philip Wenzel,Juergen vom Dahl,Burkhard Sievers,Jan Pulz,Sebastian Schellong,Peter Clemmensen,Matthias Muller-Hennessen,Tienush Rassaf,Jozsef Falukozi,Zoltán Ruzsa,János Tomcsányi,Zoltán Csanádi,Béla Herczeg,Zsolt Kõszegi,András Vorobcsuk,Róbert Gábor Kiss,Csaba Baranyai,Csaba András Dézsi,Béla Merkely,Géza Lupkovics,Romando Rossini,Marino Scherillo,Pier Sergio Saba,Gianluca Campo,Leonardo Calò,Daniele Nassiacos,Giorgio Quadri,Alessandro Sciahbasi,Giancarlo Marenzi,Bernhard Reimers,Gian Piero Perna,Salvatore Saccà,Luciano Fattore,Claudio Brunelli,Andrea Picchi,Takehiko Kuramochi,Kazuhisa Kondo,Takahiko Aoyama,Takashi Kudoh,Tadashi Yamamoto,Tomofumi Takaya,Yasushi Mukai,Kazuki Fukui,Nobuyuki Morioka,Kenji Andò,Atsushi Yamamuro,Yasuhiro Morita,Yasuaki Koga,Tetsuya Watanabe,Tomohiro Sakamoto,Tadao Shibasaki,Daisuke Mizushima,Akihiko Takahashi,Taishi Yonetsu,Tsunekazu Kakuta,Hidetaka Nishina,Rohit M. Oemrawsingh,Reinhart Dorman,Ton Oude Ophius,Paco Prins,N.Y.Y. al Windy,Stijntje Zoet-Nugteren,Rik Hermanides,M. van Eck,Roderick W.C. Scherptong,Jan H. Cornel,Peter Damman,Gerhard Jan Willem Bech,R. Torquay,Bas Kietselaer,Pawel Grzelakowski,Dyrbus Krzysztof,Andrzej Budaj,Paweł Miękus,Andrzej Przybylski,Maciej Zarębiński,Paweł Balsam,Joanna Szachniewicz,Marek Gierlotka,Agnieszka Tycińska,Andrés Iñíguez,Antonio Fernández‐Ortíz,Anna Carrasquer Cucarella,Marcelo Sanmartı́n,Alessandro Sionís,Héctor Bueno,Jose Luis Ferreiro Gutierrez,Luís Almenar,Ignacio González‐García,Domingo A. Pascual‐Figal,Manuel Almendro Delia,Miriam Jiménez Fernández,Mika Skeppholm,Crister Zedigh,Oskar Angerås,Jörg Lauermann,David Erlinge,Robin Gustafsson,Thomas Mooe,Alejandro Utreras,Stefan James,Per Grimfjärd,Giovanni Pedrazzini,François Mach,Stéphane Fournier,Laurent Haegeli,Jürg H. Beer,Gregor Leibundgut,Richard Kobza,Christoph Kaiser,Vijay Kunadian,Rasha Al‐Lamee,Diana A. Gorog,Sohail Khan,Jasper Trevelyan,Iqbal Toor,J. Gustav Smith,Bhaskar Purushottam,C B Treasure,Frank Arena,Amarnath Vedere,David Henderson,Syed Amir Gilani,Alonzo H. Jones,Rodolfo Carrillo-Jimenez,Eve Gillespie,Gregary Marhefka,David Wang,Charles E. Olson,Stephen R. Bloom,Faizan Iftikhar,David Brabham,John B. McGinty,Charles Thompson,James V. Talano,Wilson Ginete,Marcus Williams,Ali Mas’ud,Mehrdad Ariani,Fahed Bitar,Thomas J. Wang,Bradley Samuelson
摘要
Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition was assessed at 4 weeks. The prespecified main safety outcome was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding comparing all pooled asundexian doses with placebo. The prespecified efficacy outcome was a composite of cardiovascular death, MI, stroke, or stent thrombosis comparing pooled asundexian 20 and 50 mg doses with placebo.The median age was 68 years, 23% of participants were women, 51% had ST-segment-elevation MI, 80% were treated with aspirin plus ticagrelor or prasugrel, and 99% underwent percutaneous coronary intervention before randomization. Asundexian caused dose-related inhibition of FXIa activity, with 50 mg resulting in >90% inhibition. Over a median follow-up of 368 days, the main safety outcome occurred in 30 (7.6%), 32 (8.1%), 42 (10.5%), and 36 (9.0%) patients receiving asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian versus placebo: hazard ratio, 0.98 [90% CI, 0.71-1.35]). The efficacy outcome occurred in 27 (6.8%), 24 (6.0%), 22 (5.5%), and 22 (5.5%) patients assigned asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian 20 and 50 mg versus placebo: hazard ratio, 1.05 [90% CI, 0.69-1.61]).In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients who experienced acute MI.URL: https://www.gov; Unique identifier: NCT04304534; URL: https://www.clinicaltrialsregister.eu/ctr-search/search; Unique identifier: 2019-003244-79.